Sign In
Buy ONCT
$0.527
+0 (+0%)
At Close: Feb 28, 2025
SAN DIEGO, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today annou
Oncternal Therapeutics to Present at Stifel Virtual Healthcare Conference
04:01pm, Monday, 09'th Nov 2020
SAN DIEGO, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Oncternal Therapeutics (Nasdaq: ONCT), today announced that James Breitmeyer, M.D., Ph.D., President and Chief Executive Officer, will present a company ov
Oncternal Announces Third Quarter 2020 Financial Results and Provides Business Update
05:15pm, Wednesday, 04'th Nov 2020
SAN DIEGO, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today provi
Oncternal Therapeutics : Provides Business Update and Announces Second Quarter 2020 Financial Results | MarketScreener
08:21pm, Thursday, 06'th Aug 2020Oncternal Provides Business Update and Announces Second Quarter 2020 Financial Results
08:15pm, Thursday, 06'th Aug 2020
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today provided a business update and reported second qua
Oncternal Therapeutics'(NASDAQ:ONCT) Share Price Is Down 33% Over The Past Year.
06:37pm, Thursday, 06'th Aug 2020
While not a mind-blowing move, it is good to see that the Oncternal Therapeutics, Inc. (NASDAQ:ONCT) share price has...
Celyad Oncology annoncera prochainement les résultats financiers du premier semestre 2020 et tiendra une conférence téléphonique
12:00am, Monday, 03'rd Aug 2020
Regulatory News: Celyad Oncology SA (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) (Euronext & Nasdaq : CYAD), une société de biotechnologie de stade
Oncternal Therapeutics to Report Second Quarter 2020 Financial Results and Provide Business Update
12:00pm, Thursday, 30'th Jul 2020
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report second quarter 2020
Oncternal Therapeutics to Host Call on Cirmtuzumab and the Current Treatment Landscape for Mantle Cell Lymphoma
12:00pm, Monday, 27'th Jul 2020
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will host a call with a key opin
Oncternal Therapeutics to Host Call on Cirmtuzumab and the Current Treatment Landscape for Mantle Cell Lymphoma
12:00am, Monday, 27'th Jul 2020
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today
Oncternal Therapeutics Announces $6.2 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
12:00pm, Monday, 20'th Jul 2020
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has entered into definitive agre
Oncternal Therapeutics Announces $6.2 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
12:00am, Monday, 20'th Jul 2020
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today
The Daily Biotech Pulse: Moderna To Kickstart Phase 3 Study On July 27, Immutep Awarded Antibody Patent
12:00am, Wednesday, 15'th Jul 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 14)
Altimmune Inc (NASDAQ: ALT...
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the United States Food and Drug Adm
Oncternal Therapeutics Announces Increased Focus of the Cirmtuzumab ROR1 Antibody Program on Mantle Cell Lymphoma
11:45am, Tuesday, 30'th Jun 2020
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced an updated clinical strategy for its inv
